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Aims: To investigate treatment patterns and achievement of glycemic targets in patients
with type 2 diabetes mellitus treated with basal insulin in a real-world setting, and to deter-
mine physicians’ beliefs and practices regarding these patients.
Methods: This study had two components; a retrospective analysis using a US claims data-
base of patient and treatment data, and a survey of physicians’ beliefs and practices.
Results: A total of 39,074 patients treated with basal insulin were included in this analysis.
The proportion of patients achieving HbA1c < 7.0% (53 mmol/mol) was similar in ongoing
basal insulin users at baseline (26%) and at 3 months follow-up (27%). The number of
new initiators achieving HbA1c < 7.0% (53 mmol/mol) increased from baseline (11%) to
3 months (27%). In the physician survey component, the majority of physicians indicated
they would continue to increase basal insulin dose as long as was needed to reach HbA1c/-
fasting blood glucose goals (85% of physicians treating ‘not on-goal’ patients, 78% of physi-
cians treating ‘on-goal’ patients). Physician-perceived barriers to insulin intensification
included patient’s lifestyle, non-adherence, and concerns about out-of-pocket costs.
Conclusions: A large proportion of patients on insulin-based therapy fail to reach glycemic
goals. More education of clinicians may improve insulin intensification rates and increase
the proportion of patients reaching glycemic targets.
 2016 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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It is estimated that approximately 29.1 million people in the
US have diabetes, of whom approximately 8.1 million are
undiagnosed [1]. The majority (90–95%) of adults diagnosed
have type 2 diabetes mellitus (T2DM) [1]. Diabetes is associ-
ated with significant morbidity and mortality, as well as con-
siderable health care costs; the estimated total cost (direct
plus indirect costs) associated with diabetes in the US in
2012 was $245 billion [1]. The American Diabetes Association
(ADA) Standards of Medical Care in Diabetes recommends
glycemic targets of glycated hemoglobin (HbA1c) < 7.0%
(53 mmol/mol) and fasting blood glucose (FBG) of 80–130 mg/
dL for most adults with T2DM [2]. Studies have shown that
low or high mean HbA1c values (<6.5% [48 mmol/mol] or
>9.0% [75 mmol/mol]) are associated with increased mortality
and cardiac events [3,4]. Given the progressive nature of
T2DM, many patients will eventually require intensification
of initial oral antidiabetes drug (OAD) treatment with the
addition of a second-line OAD, insulin, or non-insulin inject-
able, with some of these patients requiring further treatment
intensification to maintain glycemic targets as recommended
by the ADA Standards of Medical Care in Diabetes [2], the
ADA/European Association for the Study of Diabetes (EASD)
guidelines [5], and the American Association of Clinical
Endocrinologists (AACE)/American College of Endocrinology
(ACE) comprehensive diabetes management algorithm [6].
Despite the availability of clinical guidelines and the wide
variety of antidiabetes drugs that have reached the market, it
is estimated that only about half of the patients with T2DM in
the US achieve the HbA1c target of <7.0% (53 mmol/mol) [7].
A systematic review of 218 randomized clinical trials (RCTs)
found that only 39% of 21,615 patientswith T2DM treatedwith
basal insulin achieved HbA1c < 7.0% (53 mmol/mol) [8]. A pri-
mary care database analysis of 4062 patientswith T2DM found
that after oneyear of basal insulin therapy, only 7% reached the
glycemic target of HbA1c 6 6.5% (48 mmol/mol) [9]. In a study
of data from 11 RCTs and one electronic medical record (EMR)
database, about 50%of patients inRCTs achievedHbA1c < 7.0%
(53 mmol/mol), compared to about 27% of patients in the EMR
database [10]. A retrospective study involving a European EMR
database found that after twoyears of basal insulin therapy17–
34% of patients reached HbA1c < 7.0% (53 mmol/mol) [11]. In
addition, insulin intensification appears to be underused by
both primary care physicians (PCPs) and specialists despite
the progression of patient’s T2DM [12]. The factors underlying
the non-attainment of these goals from a physician perspec-
tive are unclear, and an insight into these factors may assist
in the understanding of the observed trends in glycemic
control.
This study consisted of two components: the first was a
retrospective study using a large US integrated-claims data-
base to (a) estimate the proportion of patients with T2DM
treated with basal insulin (alone or in combination with other
injectables) achieving HbA1c and FBG targets in a real-world
setting, and (b) investigate the treatment patterns of those
patients who do not achieve these targets; the second compo-nent was an internet-based survey conducted among physi-
cians to (a) better understand patient management from a
physician’s perspective, (b) ascertain the physicians’ opinions
as to why patients do not achieve glycemic targets despite
basal insulin use, and (c) ascertain the characteristics and
beliefs of the physicians of patients who do achieve glycemic
targets.
2. Methods
2.1. Study
The study consisted of two components: a retrospective anal-
ysis of administrative claims data from the HealthCore Inte-
grated Research DatabaseSM (HIRD; HealthCore Inc.,
Wilmington, DE, USA), and a cross-sectional survey of physi-
cians who used basal insulin to treat patients with T2DM and
who had claims in the HIRD. The HIRD includes medical and
pharmacy claims data and enrollment information for
approximately 38 million patients associated with a large US
private payer, and diagnostic laboratory testing results for
over 11 million patients.
2.2. Retrospective database analysis
2.2.1. Study design and patients
Inclusion criteria for this analysis were: adult patient aged
P18 years;P1 inpatient/emergency department (ED) medical
claim orP2 outpatient visits and a diagnosis of T2DM (ICD-9-
CM diagnosis codes: 250.x0 or 250.x2) [13]; P2 pharmacy
claims for basal insulin therapy (insulin glargine 100 units/
mL, insulin detemir, or NPH insulin) from July 2006 through
September 2012; and continuous medical coverage (including
both commercial and Medicare Advantage plans) 6 months
before index date (baseline period) and 12 months after the
index date (observation period).
The index date was defined as the date of the first filled
prescription for basal insulin during the period July 2006
through September 2012. Patients were grouped into two
cohorts: new initiators, defined as patients without any
claims for basal insulin or any other injectable antidiabetes
therapy during the baseline period, and ongoing users,
defined as patients with P1 claim for basal insulin during
the baseline period (patients with claims for other injectable
antidiabetes therapies in addition to basal insulin were also
included). Baseline characteristics were assessed over the
baseline period and included demographic data, comorbidi-
ties, and medication utilization.
Data assessed during the baseline period and at months 3,
6, and 12 of the 12-month observation period following the
index date included treatment patterns (use of basal insulin
[insulin glargine 100 units/mL, insulin detemir, or NPH insu-
lin], short-acting [regular] insulin, rapid-acting [insulin
aspart, insulin lispro, insulin glulisine], pre-mix insulin,
OADs, and non-insulin injectables) and HbA1c and FBG goal
attainment (in those patients with available laboratory
results). The 3-, 6- and 12-month timeframes were defined
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271–450 days, respectively. Only patients with sufficient
follow-up time were included for analysis in each observation
period.
2.2.2. Statistical analyses
Descriptive analysis was performed for all claims metrics. No
statistical comparisons of the cohorts in the retrospective
database analysis were performed.
2.3. Physician survey
2.3.1. Study design
This was an online survey of physicians (PCPs and endocri-
nologists) prescribing basal insulin to patients with T2DM
who were identified from medical and pharmacy claims data
in the HIRD. This sample population was not designed to
overlap with the sample populations used for the claims anal-
ysis. The survey was administered online, May through Octo-
ber 2014, to physicians who responded to an invitation, and
comprised two modules: one module for patients classified
by their physician as ‘on-goal’ and one module for patients
classified as ‘not on-goal’ for HbA1c.
The survey domains included patient demographics and
clinical characteristics, physician characteristics (including
age, gender, and specialization), treatment considerations,
patient barriers to the initiation or titration of basal insulin
therapy, patient attitudes or behaviors that helped patients
remain ‘on-goal’, and physician attitudes regarding basal
insulin initiation and intensification. Survey questions were
primarily close-ended, with ‘yes/no’ or Likert scale-type
response categories. All survey-related materials were
reviewed and approved by a central institutional review
board. Patient-level data were handled in compliance with
the Health Insurance Portability and Accountability Act
(HIPAA) regulations. Any information that could uniquely
identify an individual patient or physician was removed from
the survey data prior to analysis and reporting.
2.3.2. Patient and physician selection
The target survey population consisted of physicians manag-
ing the care of T2DM patients being treated with basal insulin.
A two-step process was used to identify the eligible physician
survey population. First, administrative claims data were
used to identify patients from the HIRD with P1 medical
claim with an ICD-9-CM diagnosis code for T2DM orP1 phar-
macy claim for OADs, and who also had P1 pharmacy claim
for basal insulin from January 2012 through February 2013.
Patients with either commercial or Medicare Advantage
health plans were included. For each identified patient, a cor-
responding treating physician was identified based on provi-
der information made available from a review of the
patient’s medical and pharmacy claims data. Second, identi-
fied physicians were linked with at least one T2DM patient
profile. Physicians were considered suitable for participation
in the survey if they were PCPs or endocrinologists; confirmed
that they were the primary provider of diabetes care for the
selected patient(s); had prescribed basal insulin for the
selected patient; and had seen the selected patient during
the previous 12 months. For each identified patient,physicians were then asked whether the patient reached the
physician-set HbA1c goal; if the physician answered ‘yes’
the patient was classified as ‘on goal’, and if they answered
‘no’ the patient was classified as ‘not on-goal’. Physicians
were randomly presented with the survey module for either
one ‘on-goal’ patient or one ‘not on-goal’ patient. Each physi-
cian was able to complete modules for a maximum of 2
patients. After completing the primary module (e.g. a profile
for a ‘not on-goal’ patient), and assuming the physician had
at least 2 qualifying patients, physicians were invited to com-
plete an optional second module for a different profile of
patient (i.e. an ‘on-goal’ patient). Physicians were asked to
obtain the medical chart of their identified patient(s) in order
to verify and provide updated information regarding the
patient’s profile consisting of current age, gender, duration
of T2DM, the most recent HbA1c level and body mass index.
Physicians who completed one module received $125 com-
pensation for the approximately 30-min survey; physicians
who also completed the second module for a second patient
received an additional $75.
2.3.3. Statistical analyses
Descriptive analysis was performed for all survey responses.
As the ‘on-goal’ and ‘not on-goal’ modules of the survey pur-
sued different objectives, no statistical comparisons were per-
formed across the modules.3. Results
3.1. Retrospective database analysis
3.1.1. Baseline characteristics
A total of 39,074 patients were included in the retrospective
claims analysis (Supplementary Fig. 1). Of these, 17,502 were
ongoing users of basal insulin and 21,572 were new initiators
of basal insulin. Patient demographics were similar across the
two groups (Table 1). Metformin, sulfonylureas, and thiazo-
lidinediones were the most frequently prescribed antidia-
betes medications for all patients during the baseline
period; the mean number of OADs was 0.8 for ongoing users
of basal insulin and 1.3 for new initiators of basal insulin
(Table 1). During the baseline period, 48.4% of ongoing users
were prescribed both insulin and OADs. Of ongoing insulin
users, the majority (77.4%) were prescribed insulin glargine
100 units/mL; 23.7% were prescribed NPH insulin; 1.7% were
prescribed insulin detemir; 52.9% had prescription fills for
short- or rapid-acting insulin; and 5.6% used non-insulin
injectables during the baseline period. 32.7% of new initiators
did not use any antidiabetes medications, and 67.4% used
OADs only.
3.1.2. Glycemic control
At baseline, HbA1c data were available for 19.2% of all
patients (n = 7483); 10.5% of patients had baseline and 3-
month data, 10.3% had baseline and 6-month data, and
11.3% had baseline and 12-month data. At baseline, mean
HbA1c was 8.9% (74 mmol/mol) in all patients, 8.1%
(65 mmol/mol) in ongoing basal insulin users (n = 3096) and
9.5% (80 mmol/mol) in new initiators (n = 4387). The mean
Table 1 – Baseline demographics and medication use: database analysis.
All patients (N = 39,074) Ongoing users of basal insulin (n = 17,502) New initiators of basal insulin (n = 21,572)
Age at index date (years), mean (SD) 55.2 (13.7) 54.8 (13.9) 55.5 (13.6)
Gender: female, n (%) 17,420 (44.6) 7894 (45.1) 9526 (44.2)
Region, n (%)
Northeast 7866 (20.1) 3916 (22.4) 3950 (18.3)
Midwest 11,351 (29.1) 4855 (27.7) 6496 (30.1)
South 11,739 (30) 4763 (27.2) 6976 (32.3)
West 6854 (17.5) 3210 (18.3) 3644 (16.9)
Unknown/missing 1264 (3.2) 758 (4.3) 506 (2.4)
Health plan type, n (%)
HMO 10,592 (27.1) 5157 (29.5) 5435 (25.2)
PPO 20,867 (53.4) 9832 (56.2) 11,035 (51.2)
CDHP 652 (1.7) 3 (0.0) 649 (3.0)
Other 6963 (17.8) 2510 (14.3) 4453 (20.6)
Medicare advantage, n (%) 5882 (15.1) 2135 (12.2) 3747 (17.4)
QCI, mean (SD) 1 (1.2) 1 (1.2) 1 (1.2)
Comorbidities, n (%)
Hypertension 22,919 (58.7) 9368 (53.5) 13,551 (62.8)
Hyperlipidemia 21,203 (54.3) 8997 (51.4) 12,206 (56.6)
Diabetes with chronic complications 8839 (22.6) 4666 (26.7) 4173 (19.3)
Coronary heart disease 7621 (19.5) 3310 (18.9) 4311 (20.0)
Retinopathy 5433 (13.9) 3404 (19.5) 2029 (9.4)
Neuropathy 5125 (13.1) 2703 (15.4) 2422 (11.2)
Chronic pulmonary disease 4579 (11.7) 1729 (9.9) 2850 (13.2)
Congestive heart failure 3835 (9.8) 1494 (8.5) 2341 (10.9)
Obesity 3684 (9.4) 1196 (6.8) 2488 (11.5)
Antihyperglycemic medication, n (%)
Metformin 14,997 (38.4) 5462 (31.2) 9535 (44.2)
Thiazolidinediones 9013 (23.1) 4061 (23.2) 4952 (23.0)
Sulfonylureas 12,876 (33.0) 3618 (20.7) 9258 (42.9)
DPP-4 inhibitors 2974 (7.6) 5 (0.0) 2969 (13.8)
a-glucosidase inhibitors 323 (0.8) 124 (0.7) 199 (0.9)
Meglitinides 1314 (3.4) 562 (3.2) 752 (3.5)
Injectable incretin mimetics 983 (2.5) 983 (5.6) 0 (0.0)
Number of OADs, mean (SD) 1.1 (1.1) 0.8 (1) 1.3 (1.1)
CDHP, consumer-driven health plan; DPP-4, dipeptidyl peptidase 4; HMO, health maintenance organization; N/A, not applicable; OADs, oral antidiabetic drugs; PPO, preferred provider organization;
QCI, Quan Charlson Comorbidity Index; SD, standard deviation.
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d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 1 ( 2 0 1 6 ) 1 7 –2 6 21HbA1c in ongoing basal insulin users showed little change
from baseline at 3, 6 or 12 months (Fig. 1A); in contrast,
new initiators had a mean reduction in HbA1c of 1.3%
(14.2 mmol/mol) at 3 months, which was sustained for up to
12 months (Fig. 1A). In ongoing basal insulin users, theFig. 1 – For patients with available HbA1c data, (A) mean chang
proportion of patients achieving HbA1c < 7.0% (53 mmol/mol); (C
(75 mmol/mol). Results are for patients with available data at ba
patients had data available at all 3 time points.proportion of patients achieving HbA1c < 7.0% (53 mmol/mol)
was similar throughout the study period, whereas the propor-
tion of new initiators achieving HbA1c < 7.0% (53 mmol/mol)
increased markedly from baseline to 3 months (Fig. 1B). Sim-
ilarly, andwhile the proportion of patients with HbA1cP 9.0%e in HbA1c from baseline at 3, 6 and 12 months; (B) the
) the proportion of patients with HbA1cP 9.0%
seline and each individual follow-up time point. Not all
22 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 2 1 ( 2 0 1 6 ) 1 7 –2 6(75 mmol/mol) declined only slightly among ongoing basal
insulin users, there was a marked decrease from baseline to
3 months among new initiators (Fig. 1C).
FBG data were available for only a small subset of patients.
At baseline, data were available for 1.3% of all patients
(n = 530), and 0.4% of patients had baseline, 3-month, 6-
month, and 12-month data. At baseline, mean FBG was
183.6 mg/dL in all patients, 147.5 mg/dL in ongoing users
(n = 64), and 188.5 mg/dL in new initiators (n = 466). Over the
study period, ongoing basal insulin users showed a mean
increase in FBG levels, while new initiators showed a mean
decrease (Supplementary Fig. 2A). Although the proportion
of new initiators who achieved the FBG goal of <130 mg/dL
increased over the study period, a significant proportion of
ongoing users and new initiators did not achieve this goal
(Supplementary Fig. 2B).
3.1.3. Treatment patterns at 6 months
At 6 months, among ongoing basal insulin users, 89.4% had
P1 prescription fill for basal insulin (69.2% for insulin glar-
gine, 18.9% for NPH insulin, and 3.5% for insulin detemir). In
addition, 41.9% of ongoing users also filled a prescription for
rapid-acting insulin, and 5.7% had a prescription fill for
non-insulin injectable; 40.7% were prescribed insulin and at
least one OAD. At 6 months, among new initiators of basal
insulin, 80.0% had P1 prescription fill for basal insulin
(58.6% for insulin glargine, 6.0% for NPH insulin, 16.3% insulin
detemir). In addition, 20.0% of users also filled a prescription
for rapid-acting insulin, and 2.8% also had a fill for a non-
insulin injectable; 49.1% used insulin in conjunction with at
least one OAD. These treatment pattern results were similar
at 3 and 12 months (data not shown).
3.1.4. Treatment patterns at 6 months for patients not
achieving HbA1c < 7.0%
For patients with HbA1c data not achieving HbA1c < 7.0%
(53 mmol/mol) at 6 months (n = 4190) but receiving basal insu-
lin: 16.4% were prescribed basal insulin only, 32.6% basal
insulin and rapid-acting insulin, and 5.1% basal insulin andTable 2 – Treatment patterns at 6 months for patients with HbA
All patients Ongoi
(n = 4190)b (n = 21
Bolus treatments, n (%)
Basal + rapid-acting insulin 1365 (32.6) 920 (4
Basal + short-acting insulin 214 (5.1) 166 (7
Other antihyperglycemic medications, n (%)
Basal + metformin 1521 (36.3) 674 (3
Basal + thiazolidinediones 767 (18.3) 442 (2
Basal + sulfonylureas 1110 (26.5) 411 (1
Basal + DPP-4 inhibitors 312 (7.5) 71 (3.3
Basal + a-glucosidase inhibitors 30 (0.7) 13 (0.6
Basal + meglitinides 127 (3.0) 61 (2.9
Basal + injectable incretin mimetics 228 (5.4) 160 (7
Premix 137 (3.3) 87 (4.1
Basal insulin only, n (%) 687 (16.4) 316 (1
a Patients with HbA1c data available at 6 months.
b Patients not at glycemic target with P 1 prescription fill for basal insushort-acting insulin (Table 2). More ongoing basal insulin
users had concomitant prescription fills for short- or rapid-
acting insulin compared with new initiators, while more
new initiators had concomitant prescription fills for met-
formin, sulfonylureas, or dipeptidyl peptidase-4 (DPP-4) inhi-
bitors than ongoing users (Table 2).
A similar pattern of treatment intensification was
observed for patients with FBG data and not achieving FBG
<130 mg/dL at 6 months (n = 209); 21.5% of patients had no
additional treatments, and 27.3% also added a rapid-acting
insulin.
3.2. Physician survey
3.2.1. Baseline characteristics
Of >18,000 physicianswho received fax invitations, 155 partic-
ipated in the survey. Most physicians were in primary care,
were male, and had been in practice for 20 years; mean age
was 52 years (Supplementary Table 1). 72 physicians (46.4%)
completed the ‘not on-goal’ module only, 55 (35.5%) the ‘on-
goal’ module only, and 28 (18.1%) competed both modules,
providing information on 183 patients (83 ‘on-goal’ and 100
‘not on-goal’). The demographic characteristics of the ‘not
on-goal’ and ‘on-goal’ patients were similar (Supplementary
Table 2). The most common physician-reported HbA1c goals
were >6.5 (48 mmol/mol) to 67.0% (53 mmol/mol) (49.0% for
‘not on-goal’ patients and 45.8% for ‘on-goal’ patients). More
stringent HbA1c goals (66.5% [48 mmol/mol]) were reported
for 34.0% of ‘not on-goal’ patients and 41.0% of ‘on-goal’
patients. Less stringent goals (>7.0 [53 mmol/mol] to 68.0%
[64 mmol/mol]) were reported for 17.0% of ’not on-goal’
patients and 12.0% of ‘on-goal’ patients. The majority of
physicians considered target FBG to be 100 to <130 mg/dL
(70.0% for ‘not on-goal and 73.5% for ‘on-goal’ patients).
3.2.2. Initial basal insulin regimen and titration approach
Patients were prescribed basal insulin for a mean (standard
deviation [SD]) of 6.8 (1.59) years (‘not on-goal’ patients: 6.7
[1.64] years; ‘on-goal’ patients: 7.0 [1.51] years). The most1cP 7.0%: adatabase analysis.
ng users of basal insulin New initiators of basal insulin
42)b (n = 2048)b
3.0) 445 (21.7)
.8) 48 (2.3)
1.5) 847 (41.4)
0.6) 325 (15.9)
9.2) 699 (34.1)
) 241 (11.8)
) 17 (0.8)
) 66 (3.2)
.5) 68 (3.3)
) 50 (2.4)
4.8) 371 (18.1)
lin during 3- and 6-month follow-up.
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insulin alone (19% of ‘not on-goal’ patients; 27% of ‘on-goal’
patients) or basal insulin and OADs (58% of ‘not on-goal’
patients, 53% of ‘on-goal’ patients) (Supplementary Fig. 3).
The three main reasons chosen by physicians for the choice
of initial basal insulin regimen were the same for both ‘on-
goal’ and ‘not on-goal’ patients, and reflected the physicians’
perceptions of their patients’ inability to reach glycemic goals
(Table 3). Overall, 83% of physicians reported they would con-
tinue to increase a patient’s basal insulin dose for as long as
was needed to reach the HbA1c/FBG targets, while 20% would
increase the insulin dose until the patient complained of
intolerable hypoglycemia (Table 3). After initiating insulin
therapy, 65.6% of physicians reported that they would educate
their patients on self-titrating their basal insulin dose (63.0%
‘not on-goal’ and 68.7% ‘on-goal‘), while 15.8% of physicians
indicated that they would not titrate insulin dose at all
(12.0% ‘not on-goal’ and 20.5% ‘on-goal‘).
3.2.3. Barriers to initiation or titration of basal insulin
therapy in ‘not on-goal’ patients
For ‘not on-goal’ patients, the main clinical barriers to the ini-
tiation or titration of basal insulin therapy as perceived by
physicians were patients’ lifestyle, including diet and exercise
(selected by 52% of physicians), and non-adherence to exist-
ing medication (selected by 36% of physicians) (Supplemen-
tary Table 3). Patients’ concern about out-of-pocket
expenses (selected by 48% of physicians) and reluctance to
consider basal insulin treatment (selected by 35% of physi-
cians) were the main patient-related barriers chosen by
physicians (Supplementary Table 3). Only 19% of physicians
reported patients’ fear of hypoglycemia, and 14% of physi-
cians reported concerns about weight gain as barriers to the
initiation or titration of basal insulin.
3.2.4. Management of ‘on-goal’ patients
A high proportion of physicians (39.8%) would consider
their patient as no longer ‘on-goal’ if their HbA1c reached
7.5% (58 mmol/mol); 10.8% would consider HbA1cP 8.5
(69 mmol/mol) as no longer ‘on-goal’. When considering theTable 3 – Five main reasons for choosing initial basal insulin re
Five main reasons for choice of initial basal insulin regimen, n (%)a
Patient inability to reach HbA1c goal with previous therapies
How far patient is/was from HbA1c target
Patient’s current FBG level
Patient’s eating habits
Patient’s current PPG level
Five main criteria determining how long physicians would continue to
As long as needed to reach patient’s HbA1c/FBG goal
Until HbA1c goal is/was reached within 6 months
Until FBG goal is/was reached within 6 months
Until patient complains of intolerable hypoglycemia
Until reaching a basal insulin dose of 0.5 U/kg within 6 months
FBG, fasting blood glucose; PPG, postprandial blood glucose.
a Physicians could choose more than one option.hypothetical situation of their ‘on-goal’ patient no longer being
at goal, physicians were asked to rank the most likely reasons
for this: not managing their diet correctly or gaining weight
(86.7%); not using theirmedication correctly (62.7%); or disease
progression (59.0%). Physicians were asked to rank the treat-
ment options that theywould consider if their ‘on-goal’ patient
failed tomaintain theirHbA1cgoals (Fig. 2). Thehighest ranked
options were: ‘increase basal insulin dose’, ‘review patients’
lifestyle andmedication adherence’, and ‘review patients’ pat-
terns of self-monitored glucose values’. Of these, ‘review of
patients’ lifestyle and medication adherence’, and ‘increase
basal insulindose’weremost commonly ranked asfirst choice.
4. Discussion
The data from our retrospective analysis adds to a growing
body of evidence showing that a significant proportion of
patients (50–73%) treated with basal insulin are failing to
achieve glycemic targets in the real-world [7,8,10,11]. In this
current analysis, the initiation of basal insulin therapy was
associated with a mean decrease in HbA1c of 1.3%
(14.2 mmol/mol) at 3 months, which was sustained for up to
12 months, and an increase in the proportion of patients
achieving the glycemic targets of HbA1c < 7.0% (53 mmol/mol)
(27% at 3 months versus 11% at baseline) and FBG < 130 mg/dL
(44% at 3 months versus 32% at baseline). Patients in the
newly initiated basal insulin group had higher baseline HbA1c
levels than those on ongoing basal insulin therapy (9.5%
[80 mmol/mol] vs 8.1% [65 mmol/mol], respectively). In this
context, the reduction in HbA1c and increase in the propor-
tion of patients meeting HbA1c targets in the new initiators,
compared to the small changes seen with ongoing basal insu-
lin users, is expected. However, the majority of new initiators
and ongoing users of basal insulin included in this study did
not achieve either HbA1c (75% and 72%, respectively) or FBG
(55% and 55%, respectively) targets, as recommended by
ADA/EASD guidelines [5], at 12 months of follow-up. These
results are in line with data from the National Health and
Nutrition Examination Surveys (NHANES), which reported
that for the years 2007–2010, only 30.3% of adult patients withgimen and top five choices for titration approach.
‘Not-on-goal’ patients ‘On-goal’ patients
(n = 100) (n = 83)
87 (87.0) 59 (71.1)
83 (83.0) 58 (69.9)
71 (71.0) 57 (68.7)
60 (60.0) 32 (38.6)
55 (55.0) 34 (41.0)
increase basal insulin dose, n (%)a
85 (85.0) 65 (78.3)
52 (52.0) 47 (56.6)
43 (43.0) 43 (51.8)
23 (23.0) 14 (16.9)
12 (12.0) 14 (16.9)
Fig. 2 – The proportion of physicians of ‘on-goal’ patients selecting each treatment option as first, second, or third choice
(n = 83). Physicians were asked to rank their top five treatment options to help their patient get back on goal, if their ‘on-goal’
patient was no longer reaching goal.
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<7.0% (53 mmol/mol) compared with 25.8% of patients for the
years 1999–2002 [7]. Although the NHANES data for 2007–2010
represent an improvement on those from a decade previously,
they are clearly far from optimal.
The results of this study reflect the challenges in achieving
glycemic targets either in new initiators or ongoing users. It is
also surprising that new initiators do not reach goal, consid-
ering the response of new initiators is carefully monitored;
it would be more understandable that ongoing users of basal
insulin would become out of control after being on insulin.
Barriers to achieving optimal glycemic control are likely to
be multifactorial, and linked to a number of patient-,
physician-, and treatment-related factors; an understanding
of these barriers is important if the continued trend of poor
glycemic control is to be improved. Our survey assessed
physicians’ attitudes and behaviors in the management of
basal insulin therapy and physician-perceived barriers to
optimal glycemic control. Treatment guidelines recommend
insulin initiation and subsequent insulin intensification (e.g.
adding bolus insulin, increasing dosing frequency) to achieve
glycemic control [2,5,6]; however, there is a growing body of
evidence showing frequent deviations from treatment guide-
lines with delayed insulin intensification.
A recent systematic review found that providers across
both primary and specialty care settings frequently fail to
intensify insulin regimens despite patients’ clinical status,
and, even where regimens are intensified, many patients
have HbA1c above guideline targets, indicating a need for fur-
ther intensification [12]. In our analysis, the treatment pat-
terns for patients not achieving glycemic targets suggest
that some intensification of therapeutic regimens was under-
taken; however, only a relatively small proportion of both new
initiators and ongoing users who did not achieve glycemic
targets remained on basal insulin only. A high proportion of
physicians in our survey (35%) stated they would increasebasal insulin dose as their first choice measure in patients
who no longer met glycemic targets.
The reasons behind the apparent reluctance of many
physicians to intensify therapy are unclear, but may be due
to factors such as concerns about the risk of hypoglycemia
and weight gain, uncertainty about patient compliance, lim-
ited awareness of, or disagreement with, treatment guideli-
nes, and in older patients, worries about complications or
comorbidities [12,14,15]. A recent survey of 252 primary care
providers found that there was a wide range of beliefs regard-
ing the glycemic goals of their patients, treatment intensifica-
tion, and obstacles to achieving optimal glycemic control;
these included poor compliance, lack of physician time with
patients, patient resistance to adopting a heathy lifestyle,
and psychological issues [17]. Despite these differences in
opinion, there was a consistency in HbA1c levels across all
providers; this suggests that rather than targeting interven-
tion at the provider level, the best approach to resolving bar-
riers to achieving optimal glycemic control would be to focus
at the health system level [17]. In our physician survey, fear of
hypoglycemia and weight gain were perceived by physicians
as less important to the initiation and titration of basal insu-
lin therapy than factors such as patient lifestyle (diet and
exercise), self-monitoring abilities, non-adherence, and out-
of-pocket costs. Poor adherence to diabetes medication,
including both OADs and insulin, is a well-recognized prob-
lem [18]; however, clinical inertia, or failure to intensify phar-
macotherapy appropriately, may be as great a problem as
poor adherence in patients with T2DM not at goal, and may
be more common [19]. In this study it is interesting to note
that rapid-acting insulins were commonly used, in contrast
to glucagon-like peptide-1 (GLP-1) receptor agonists; one rea-
son for this may be due to medication costs.
In this study, physicians indicated that patients’ inability
to maintain glycemic goals was largely a result of patients
not managing their diet, weight, or medication correctly;
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given most frequently as the primary approach to failure to
maintain glycemic control.
There was also a suggestion in our survey results that
physicians may not be fully aware of, or are not fully follow-
ing, treatment guidelines, as a high proportion of insulin ini-
tiators (33%) were not on metformin, although this may have
been linked to other patient factors. Furthermore, of the main
approaches selected by physicians for intensification of basal
insulin, many relied on HbA1c rather than FBG, as recom-
mended by the ADA treatment guidelines [2] which may put
patients at risk of hypoglycemia, while one in five physicians
reported that they would increase basal insulin until patients
complained of intolerable hypoglycemia. Of the 155 physi-
cians surveyed, 137 were PCPs and only 18 were endocrinolo-
gists; PCPs may be expected to have less awareness or
experience of treating diabetes than endocrinology
specialists.
Given that hypoglycemia events, particularly severe epi-
sodes, may have potentially serious short- and long-term
consequences [20], including a higher risk of dementia [21],
fall-related fractures [22], cardiovascular events [23], and
increased mortality [24], our data suggest that there may be
a need for physician education regarding the optimal timing
of insulin dose titration and intensification of therapy. Physi-
cian education may also help improve confidence in intensi-
fying insulin therapy, and education programs have been
shown to increase the proportion of patients in whom insulin
therapy is intensified [16].
Although our study provides useful insight into current
treatment practices and physicians’ beliefs about achieving
and maintaining glycemic targets, it has a number of limita-
tions. The study samples were identified from a large US com-
mercial administrative claims database, so the results might
not be generalizable to patients enrolled in different plans
or outside the US. Comparisons across time periods and
cohorts need to be made with caution as the study did not
involve hypothesis testing or adjustments for selection bias
or confounding. Certain information such as weight, duration
of diabetes and clinical laboratory results were not available
for all patients. The proportion of patients with HbA1c values
directly available in the HIRD was low (10.5% for 3 months
post index date, 10.3% at 6 months, and 11.3% at 12 months),
although this represents thousands of patients in absolute
terms. The study did not investigate if patients with directly
available HbA1c results were systematically different from
those without.
The sample size of physicians surveyed was limited, and
was not designed to overlap with the sample of patients in
the observational claims analysis; therefore results from each
part of the study are not directly comparable. Response rates
for physician surveys tend to be lower than those for non-
physician surveys because of the many challenges associated
with contacting physicians individually and within medical
groups or practices. We do not know how many of the fax
invitations reached or did not reach their intended physician
recipient. The response rate may also have been affected if
physicians were not comfortable completing surveys about
specific patients for whom medical record information wasrequired. Although the study’s low response rate raises con-
cerns about potential non-response bias, studies have found
physician surveys to be less affected by non-response than
other types of surveys because the physician population
tends to be more homogeneous with regard to knowledge,
training, attitudes and behaviors [25].
As with all survey studies, respondents may behave differ-
ently from non-respondents, and self-reports are subject to
recall bias. Other physician barriers to participating in this
type of survey may have included the time required to com-
plete the survey, the available compensation, and a reluc-
tance to provide information or responses relating to
clinical medical record information of identified patients.
In conclusion, this retrospective analysis of a large cohort
of patients with T2DM treated in routine clinical practice
highlights the fact that a large proportion of patients on
insulin-based therapy are failing to reach glycemic goals,
despite recommendations and guidance for insulin intensifi-
cation [2,6]. The main perceived barriers to insulin intensifi-
cation reported by physicians were patients’ lifestyle, non-
adherence, and concerns about out-of-pocket costs; fear of
hypoglycemia and weight changes were considered to be less
important. Our survey also suggests that physicians may not
be fully aware of, or are not fully following, treatment guide-
lines. More and up-to-date education for patients and physi-
cians may be a promising strategy to improve insulin
intensification rates, and thus increase the proportion of
patients reaching glycemic targets.Conflicts of interest
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